The neurological disorders segment is anticipated to witness a growth rate of 22.3% between 2023 – 2032 as AAV vectors play a pivotal role in delivering therapeutic genes to specific cells within the nervous system, and they can either integrate into the host genome or persist as episomal structures, offering prolonged therapeutic benefits. Read More